TOVX
Theriva Biologics Inc.NYSE MKT
Healthcare • Biotechnology
$0.17-1.13%
Close Nov 6, 2026
- Market cap
- $7.64M
- 1 month
- -26.7%
- 3 months
- -27.9%
- 1 year
- -43.8%
- 52-week range
- $0.17$0.41
- Dividend
- No dividends on record
- Short interest
- 4.1% of float1.8M shares · settled Oct 15, 2026 · +7.8% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $300K
- Net income
- -$11.62M
- Free cash flow
- -$12.38M
- Book value
- $12.19M
- Total debt
- $3.55M
- P/E
- —
- Price / sales
- 25.5×
- Price / book
- 0.6×
- FCF yield
- -162.0%
- Net margin
- -3,872.7%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
Read more
Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
- Website
- therivabio.com
- Headquarters
- Rockville, MD, United States
- Employees
- 15
- Listed
- Dec 18, 2006
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 27, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 11, 2026 | — | — | — | -$3.3M | -$3.2M |
| Mar 2026filed May 5, 2026 | $300.0K | — | 92.0% | -$2.1M | -$2.0M |
| Dec 2025filed Mar 12, 2026 | — | — | — | -$2.1M | -$2.0M |
| Sep 2025filed Nov 12, 2025 | — | — | — | -$4.4M | -$4.4M |
| Jun 2025filed Aug 11, 2025 | — | — | — | -$13.1M | -$13.1M |
| Mar 2025filed May 14, 2025 | — | — | — | -$4.4M | -$4.3M |
| Dec 2024filed Mar 6, 2025 | $154.0K | -79.7% | — | -$4.4M | -$4.4M |
| Sep 2024filed Sep 30, 2024 | — | — | — | -$7.9M | -$7.7M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 12, 2026 | — | — | — | -$15.0M | -$25.2M |
| Dec 2024filed Mar 6, 2025 | — | — | — | -$26.3M | -$25.7M |
| Dec 2023filed Mar 25, 2024 | — | — | — | -$21.4M | -$18.3M |
| Dec 2022filed Mar 30, 2023 | — | — | — | -$21.6M | -$19.7M |
| Dec 2021filed Dec 31, 2021 | — | — | — | -$14.3M | -$14.2M |
| Dec 2020filed Dec 31, 2020 | — | — | — | -$10.2M | -$10.0M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched TOVX. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
1,846,818 shares short
+134,285 shares (+7.8%) vs Sep 30, 2026
4.1% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
1,712,533 shares short
+123,029 shares (+7.7%) vs Sep 15, 2026
3.8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
1,589,504 shares short
-174,558 shares (-9.9%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
1,764,062 shares short
+47,064 shares (+2.7%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
1,716,998 shares short
-398,926 shares (-18.9%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
2,115,924 shares short
-220,574 shares (-9.4%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind TOVX’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
The newest stored ex-date is Dec 27, 2007. These are historical records; a current dividend schedule is unavailable.
USD 0.0475 per share
Ex-dividend date: Dec 27, 2007
Recorded pay date: Jan 10, 2008 (past date)
Cash dividend · Polygon event record
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 25 · reverse split
Effective Aug 26, 2024
Each 25 pre-split shares become 1 post-split share.
Source: EODHD
1 for 10 · reverse split
Effective Jul 25, 2022
Each 10 pre-split shares become 1 post-split share.
Source: EODHD
1 for 35 · reverse split
Effective Aug 13, 2018
Each 35 pre-split shares become 1 post-split share.
Source: EODHD
1 for 3 · reverse split
Effective Apr 25, 2007
Each 3 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if TOVX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
6 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Aug 14, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
24 filers reported a long position in TOVX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
91.6%
of the 2M shares 13-F filers reported
Moves vs Q1 2026
2 added4 trimmed
2 new · 2 unchanged
Net shares held
-4.5%
across the 8 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | $121.5K · 486.2K shares | 486.2K | +152.7% |
| 2 | JANE STREET GROUP, LLC | $83K · 331.9K shares | 331.9K | +87.5% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | $73.6K · 294K shares | 294K | -34.7% |
| 4 | VANGUARD FIDUCIARY TRUST CO | $60.4K · 241.8K shares | 241.8K | Unchanged |
| 5 | Ikarian Capital, LLC | $28K · 112.1K shares | 112.1K | Unchanged |
| 6 | Virtu Financial LLC | $22K · 87.1K shares | 87.1K | -65.6% |
| 7 | NORTHERN TRUST CORP | $20.7K · 82.7K shares | 82.7K | New |
| 8 | RENAISSANCE TECHNOLOGIES LLC | $15.9K · 63.7K shares | 63.7K | New |
| 9 | UBS Group AG | $15.3K · 61.1K shares | 61.1K | -72.9% |
| 10 | XTX Topco Ltd | $13.5K · 53.9K shares | 53.9K | -43.1% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inGet the Full Analysis for TOVX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.